{"result": "{\n    \"title\": \"Clinical Trials and Breast Cancer Treatment\",\n    \"summary\": \"The community revolves around clinical trials and breast cancer treatment, with entities such as Clinical Trials, Combination Therapy, Monotherapy, Grade 3\u20134 Adverse Events, and Progression-Free Survival being related to each other through various relationships.\",\n    \"rating\": 6.5,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for significant advancements in breast cancer treatment and the potential for adverse events.\",\n    \"findings\": [\n        {\n            \"summary\": \"Clinical Trials as a central entity\",\n            \"explanation\": \"Clinical Trials is the central entity in this community, serving as the location for evaluating the safety and efficacy of new treatments for breast cancer. This entity is the common link between all other entities, suggesting its significance in the community. The relationships between Clinical Trials and other entities, such as Combination Therapy and Monotherapy, are crucial in understanding the dynamics of this community. [Data: Entities (77), Relationships (29, 137, 138)]\"\n        },\n        {\n            \"summary\": \"Combination Therapy as a significant treatment approach\",\n            \"explanation\": \"Combination Therapy is a significant treatment approach in this community, being evaluated in clinical trials to determine its safety and efficacy in treating breast cancer. The relationships between Combination Therapy and other entities, such as Pazopanib and Grade 3\u20134 Adverse Events, are crucial in understanding the dynamics of this community. [Data: Entities (235), Relationships (272, 278, 279)]\"\n        },\n        {\n            \"summary\": \"Monotherapy as an alternative treatment approach\",\n            \"explanation\": \"Monotherapy is an alternative treatment approach in this community, being evaluated in clinical trials to determine its safety and efficacy in treating breast cancer. The relationships between Monotherapy and other entities, such as Clinical Trials and Grade 3\u20134 Adverse Events, are crucial in understanding the dynamics of this community. [Data: Entities (248), Relationships (138, 280)]\"\n        },\n        {\n            \"summary\": \"Grade 3\u20134 Adverse Events as a potential concern\",\n            \"explanation\": \"Grade 3\u20134 Adverse Events are a potential concern in this community, being more common in Combination Therapy than in Monotherapy. The relationships between Grade 3\u20134 Adverse Events and other entities, such as Combination Therapy and Clinical Trials, are crucial in understanding the dynamics of this community. [Data: Entities (237), Relationships (278, 279)]\"\n        },\n        {\n            \"summary\": \"Progression-Free Survival as a key outcome measure\",\n            \"explanation\": \"Progression-Free Survival is a key outcome measure in this community, being the same in the Combination Therapy and Monotherapy arms. The relationships between Progression-Free Survival and other entities, such as Combination Therapy and Clinical Trials, are crucial in understanding the dynamics of this community. [Data: Entities (242), Relationships (279)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n77,\"\"\"CLINICAL TRIALS\"\"\",\"Here is a comprehensive summary of the data:\n\nClinical trials are studies that evaluate the effectiveness, safety, and efficacy of various treatments for breast cancer, including new systemic regimens in patients with Inflammatory Breast Cancer (IBC). These studies investigate the potential role of new treatments in patients with breast cancer, with a focus on evaluating their ability to effectively treat the disease while ensuring their safety for patients.\",4\r\n235,\"\"\"COMBINATION THERAPY\"\"\",\"Here is a comprehensive summary of the data:\n\nCombination therapy refers to a treatment approach that combines multiple medications or treatments to address a disease or condition. Specifically, it involves the use of multiple treatments together to treat a specific disease or condition, such as breast cancer. This approach is designed to provide a more effective and comprehensive treatment plan, often resulting in better patient outcomes.\",6\r\n248,\"\"\"MONOTHERAPY\"\"\",\"\"\"Monotherapy refers to the use of a single treatment to treat breast cancer.\"\"\",2\r\n237,\"\"\"GRADE 3\u20134 ADVERSE EVENTS\"\"\",\"\"\"Grade 3\u20134 adverse events refer to severe side effects of a medication.\"\"\",1\r\n242,\"\"\"PROGRESSION-FREE SURVIVAL\"\"\",\"\"\"Progression-free survival refers to the length of time during which a disease does not worsen.\"\"\",1\r\n185,\"\"\"RESPONSE RATE\"\"\",\"Here is a comprehensive summary of the data:\n\nThe \"\"RESPONSE RATE\"\" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n29,\"\"\"BREAST CANCER\"\"\",\"\"\"CLINICAL TRIALS\"\"\",\"\"\"Clinical trials are studies that evaluate the safety and efficacy of new treatments for breast cancer.\"\"\",13\r\n272,\"\"\"PAZOPANIB\"\"\",\"\"\"COMBINATION THERAPY\"\"\",\"\"\"Pazopanib is used in combination therapy to treat the disease.\"\"\",13\r\n41,\"\"\"SYSTEMIC TREATMENT\"\"\",\"\"\"CLINICAL TRIALS\"\"\",\"\"\"Systemic treatment is investigated in clinical trials to determine its efficacy and toxicity in patients with IBC.\"\"\",12\r\n137,\"\"\"CLINICAL TRIALS\"\"\",\"\"\"COMBINATION THERAPY\"\"\",\"\"\"Combination therapy is evaluated in clinical trials to determine its safety and efficacy in treating breast cancer.\"\"\",10\r\n280,\"\"\"COMBINATION THERAPY\"\"\",\"\"\"MONOTHERAPY\"\"\",\"\"\"Combination therapy and monotherapy are two approaches to treating breast cancer, with combination therapy showing a numerically highest response rate.\"\"\",8\r\n278,\"\"\"COMBINATION THERAPY\"\"\",\"\"\"GRADE 3\u20134 ADVERSE EVENTS\"\"\",\"\"\"Grade 3\u20134 adverse events are more common in combination therapy than in lapatinib monotherapy.\"\"\",7\r\n279,\"\"\"COMBINATION THERAPY\"\"\",\"\"\"PROGRESSION-FREE SURVIVAL\"\"\",\"\"\"The progression-free survival is the same in the combination therapy and lapatinib monotherapy arms.\"\"\",7\r\n249,\"\"\"RESPONSE RATE\"\"\",\"\"\"COMBINATION THERAPY\"\"\",\"\"\"The response rate is highest in the combination therapy arm.\"\"\",7\r\n138,\"\"\"CLINICAL TRIALS\"\"\",\"\"\"MONOTHERAPY\"\"\",\"\"\"Monotherapy is evaluated in clinical trials to determine its safety and efficacy in treating breast cancer.\"\"\",6\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}